Your session is about to expire
← Back to Search
Cell-free DNA Testing for Lymphoma
N/A
Recruiting
Led By Christopher Flowers, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial involves collecting DNA from blood samples of DLBCL patients to monitor their cancer and treatment response. By analyzing this DNA, doctors can identify changes in the cancer and check if any cancer cells remain after treatment.
Who is the study for?
This trial is for adults over 18 with diffuse large B-cell lymphoma (DLBCL) needing treatment. Participants must be able to give written consent and should not be pregnant or cognitively impaired. The study aims to include a diverse group from community centers across Texas.
What is being tested?
The trial is exploring the use of cell-free DNA (cfDNA) as a tool to detect genetic changes in DLBCL patients and monitor minimal residual disease after treatment. cfDNA samples are taken from blood drawn through vein puncture before and after therapy.
What are the potential side effects?
There are generally no direct side effects associated with providing a blood sample for cfDNA analysis, but some individuals may experience minor discomfort, bruising, or bleeding at the puncture site.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: cell-free DNA (cfDNA) samplesExperimental Treatment1 Intervention
cell-free DNA (cfDNA) samples from DLBCL participants before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method.
Blood will be drawn 3 times (by vein)
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for lymphoma include targeted agents, monoclonal antibodies, and novel approaches like cfDNA monitoring. Targeted agents, such as Bruton tyrosine kinase (BTK) inhibitors, work by blocking specific proteins that promote cancer cell growth.
Monoclonal antibodies, like rituximab, target specific antigens on the surface of lymphoma cells, marking them for destruction by the immune system. cfDNA monitoring is a non-invasive method that detects DNA fragments from cancer cells in the blood, helping to identify actionable genetic alterations and monitor minimal residual disease. These treatments are crucial for lymphoma patients as they offer personalized therapy options, improve treatment precision, and potentially enhance outcomes by allowing for early detection and intervention.
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
3,073 Previous Clinical Trials
1,802,809 Total Patients Enrolled
260 Trials studying Lymphoma
32,068 Patients Enrolled for Lymphoma
Christopher Flowers, MDPrincipal InvestigatorM.D. Anderson Cancer Center
3 Previous Clinical Trials
52 Total Patients Enrolled
3 Trials studying Lymphoma
52 Patients Enrolled for Lymphoma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- Not applicable.I am 18 years old or older.I have been diagnosed with diffuse large B-cell lymphoma and need treatment.
Research Study Groups:
This trial has the following groups:- Group 1: cell-free DNA (cfDNA) samples
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.